Workflow
SINOMED(688108)
icon
Search documents
8月20日科创板主力资金净流入7.30亿元
Sou Hu Cai Jing· 2025-08-20 10:15
Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 30.229 billion yuan, while the Sci-Tech Innovation Board saw a net inflow of 730 million yuan [1] - A total of 252 stocks had net inflows, while 335 stocks had net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 359 stocks rose, with two stocks hitting the daily limit up, including Shengke Communication and Haocen Software, while 218 stocks fell [1] - The top three stocks with the highest net inflow of funds were Haiguang Information (1.084 billion yuan), Han's Laser (837 million yuan), and SMIC (385 million yuan) [1] Continuous Fund Flow - There were 49 stocks with continuous net inflows for more than three trading days, with Huahai Qingke leading at eight consecutive days of inflow [1] - Conversely, 133 stocks experienced continuous net outflows, with Fudan Zhangjiang and Qi Anxin both seeing 13 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Haiguang Information: 1.084 billion yuan, 14.77% inflow rate, 4.75% increase [1] - Han's Laser: 837 million yuan, 6.76% inflow rate, 8.46% increase [1] - SMIC: 385 million yuan, 4.97% inflow rate, 3.28% increase [1] Notable Outflows - The stocks with the highest net outflows included: - Dongxin Co., Ltd.: 366 million yuan outflow, 3.75% decrease [1] - Sainuo Medical: 305 million yuan outflow [1] - Yishitong: 177 million yuan outflow [1]
8月以来这些股票实现翻倍!沪指突破十年高点,市场爆炒方向有哪些?
Hua Xia Shi Bao· 2025-08-20 02:06
Market Overview - The A-share market has entered a new round of upward momentum since August, with the Shanghai Composite Index reaching a new high since December 2021 on August 13, and further breaking through 3700 points on August 14, eventually peaking at 3746.67 points on August 19 [2][3]. Market Performance - Over 4600 stocks have risen since August, with more than 80% of stocks showing gains. Approximately 240 companies have increased by over 30%, and around 70 companies have seen gains exceeding 50% [5]. - Six companies have doubled their stock prices in August, including Sainuo Medical (194.39%), Gebijia (152%), and Shunlian Bio (117.82%) [5][6]. Industry Performance - A total of 28 sectors have recorded monthly gains exceeding 10% in August, indicating strong market momentum. The Electric Machinery II sector led with a 21.33% increase, followed by the Motorcycle and Communication Equipment sectors with gains of 19.84% and 19.50%, respectively [8][9][10]. - Other notable sectors include Home Appliance Components II and Consumer Electronics, which rose by 18.63% and 18.11%, respectively [9][10]. Investment Insights - The continuous rise in margin trading balances, reaching 2.1 trillion yuan, has been a significant driver of the market's strength, accounting for 2.32% of the A-share market's circulating market value [4]. - Analysts suggest that the market's long-term sustainability relies on performance support, with a focus on high-quality companies and sectors poised for cyclical recovery and globalization [4][11].
赛诺医疗获融资买入4.70亿元,居两市第46位
Sou Hu Cai Jing· 2025-08-20 00:02
融券方面,当日融券卖出0.00万股,净卖出0.00万股。 来源:金融界 8月19日,沪深两融数据显示,赛诺医疗获融资买入额4.70亿元,居两市第46位,当日融资偿还额4.31亿 元,净买入3852.53万元。 最近三个交易日,15日-19日,赛诺医疗分别获融资买入3.45亿元、4.03亿元、4.70亿元。 ...
赛诺医疗收盘下跌2.56%,滚动市盈率2738.89倍,总市值168.17亿元
Sou Hu Cai Jing· 2025-08-19 11:47
8月19日,赛诺医疗今日收盘40.42元,下跌2.56%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到2738.89倍,总市值168.17亿元。 来源:金融界 赛诺医疗科学技术股份有限公司的主营业务是高端介入医疗器械研发、生产、销售。公司的主要产品是 生物降解药物涂层冠脉支架系统、药物洗脱支架系统、非顺应性PTCA球囊扩张导管、PTCA球囊扩张 导管、非顺应性球囊扩张导管、冠脉球囊扩张导管、冠状动脉棘突球囊扩张导管、延长导管、颅内药物 洗脱支架系统、颅内取栓支架、颅内球囊扩张导管、负压吸引泵、一次性使用无菌吸引延长管、远端通 路导管、颅内血栓抽吸导管、微导管、远端通路导引导管、导引导管、桡动脉通路导引系统、输送导 管、球囊导引导管。 最新一期业绩显示,2025年一季报,公司实现营业收入1.01亿元,同比10.75%;净利润296.93万元,同 比277.50%,销售毛利率59.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13赛诺医疗2738.8911227.6219.32168.17亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.955 ...
高位股集体冲高回落
Mei Ri Jing Ji Xin Wen· 2025-08-19 02:40
每经AI快讯,高位股集体冲高回落,赛诺医疗回吐逾13%涨幅转跌,胜宏科技翻绿,中际旭创、新易盛 涨幅显著收窄,寒武纪突破千元关口后回落近4%。 (文章来源:每日经济新闻) ...
赛诺医疗股价创新高,融资客抢先加仓
Sou Hu Cai Jing· 2025-08-19 02:10
两融数据显示,该股最新(8月18日)两融余额为9.20亿元,其中,融资余额为9.20亿元,近10日增加 5.65亿元,环比增长159.54%。 赛诺医疗股价创出历史新高,截至9:36,该股上涨8.41%,股价报44.97元,成交量1212.77万股,成交金 额5.32亿元,换手率2.91%,该股最新A股总市值达187.10亿元,该股A股流通市值187.10亿元。 证券时报•数据宝统计显示,赛诺医疗所属的医药生物行业,目前整体涨幅为1.20%,行业内,目前股价 上涨的有410只,涨停的有福瑞股份、济民健康等3只。股价下跌的有73只,跌幅居前的有南模生物、皓 宸医疗、广誉远等,跌幅分别为4.85%、4.01%、3.58%。 7月25日公司发布上半年业绩预告,预计实现净利润1384.00万元,同比同比增长296.54%。(数据宝) 注:本文系新闻报道,不构成投资建议,股市有风险,投资需谨慎。 公司发布的一季报数据显示,一季度公司共实现营业收入1.01亿元,同比增长10.75%,实现净利润 296.93万元,同比增长277.50%,基本每股收益为0.0100元,加权平均净资产收益率0.34%。 ...
赛诺医疗:目前日常生产经营情况正常 市场环境、行业政策等均未发生重大调整
Zhi Tong Cai Jing· 2025-08-19 00:33
赛诺医疗(688108.SH)发布股票交易严重异常波动公告,公司股票交易于2025年8月14日、2025年8月15 日、2025年8月18日连续3个交易日内日收盘价格涨幅偏离值累计达到30%;公司股票交易于2025年8月7 日至2025年8月18日连续10个交易日内3次出现连续3个交易日收盘价格涨幅偏离值累计达到30%,根据 《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定,属于 股票交易严重异常波动情形。 经自查,公司目前日常生产经营情况正常,市场环境、行业政策等均未发生重大调整。敬请广大投资者 注意投资风险。 ...
赛诺医疗(688108) - 赛诺医疗科学技术股份有限公司关于股票交易严重异常波动的公告
2025-08-19 00:33
证券代码:688108 证券简称:赛诺医疗 公告编号:2025-035 赛诺医疗科学技术股份有限公司 关于股票交易严重异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 赛诺医疗科学技术股份有限公司(以下简称"赛诺医疗"或"公司")股票交 易于 2025 年 8 月 14 日、2025 年 8 月 15 日、2025 年 8 月 18 日连续 3 个交易日内日收 盘价格涨幅偏离值累计达到 30%;公司股票交易于 2025 年 8 月 7 日至 2025 年 8 月 18 日连续 10 个交易日内 3 次出现连续 3 个交易日收盘价格涨幅偏离值累计达到 30%,根 据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定,属于股票交易严重异常波动情形。 经公司自查,公司于 2025 年 7 月 22 日发布了《赛诺医疗关于公司新型药物洗 脱支架系统获得美国 FDA 附条件批准的自愿性披露公告》(公告编号:2025-029),于 2025 年 7 月 25 日发布了《 ...
赛诺医疗:不存在其他应披露而未披露的重大信息
Ge Long Hui A P P· 2025-08-19 00:23
格隆汇8月19日|赛诺医疗发布关于股票交易严重异常波动的公告,公告称,截至公告日,公司控股股 东、实际控制人及其一致行动人不存在影响公司股票交易异常波动的重大事项,不存在其他应披露而未 披露的重大信息。截至2025年8月18日,公司股票收盘价为41.48元/股,近期公司股价累计涨幅较大, 超过大部分同行业公司股价涨幅及上证指数涨幅,可能存在短期上涨过快出现的下跌风险。 ...
医药生物行业周报:医保、商保初审名单公布,关注后续进展-20250818
Donghai Securities· 2025-08-18 09:04
Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][34]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 3.08% from August 11 to August 15, 2025, ranking 10th among 31 industries and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has risen by 25.02%, ranking 4th among the industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The current PE valuation for the pharmaceutical and biotechnology sector is 31.31 times, which is at the historical median level, with a valuation premium of 145% compared to the CSI 300 index [4][20]. - Key sub-sectors that performed well include medical services, chemical pharmaceuticals, and medical devices, with respective increases of 6.60%, 3.80%, and 2.22% [4][13]. Market Performance - The pharmaceutical and biotechnology sector's performance for the week of August 11-15, 2025, showed a 3.08% increase, ranking 10th among 31 industries, and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has increased by 25.02%, ranking 4th among industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The top three performing sub-sectors were medical services, chemical pharmaceuticals, and medical devices, with increases of 6.60%, 3.80%, and 2.22% respectively [4][13]. Industry News - On August 12, 2025, the National Medical Insurance Administration announced the preliminary review list of drugs for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, with 534 drugs passing the basic medical insurance review and 121 passing the commercial insurance review [5][28]. - On August 15, 2025, the National Medical Insurance Administration issued a temporary management method for disease-based payment, aimed at reforming the payment method primarily based on disease categories [5][29]. - On August 15, 2025, Novo Nordisk announced that the supplemental new drug application for semaglutide (Wegovy) was approved by the FDA for treating metabolic dysfunction-associated fatty liver disease (MASH) in patients with mid-to-late stage liver fibrosis [5][30]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector continues to strengthen after a slight adjustment, outperforming the broader market index. It recommends focusing on investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][31]. - Recommended stocks include Betta Pharmaceuticals, Teva Pharmaceutical, Kaili Medical, Anjies, and Huaxia Eye Hospital, while stocks to watch include Kelun Pharmaceutical, Qianhong Pharmaceutical, Haier Biomedical, Kangtai Biological, and Baipusais [6][31].